Search research articles
Contact Us
Filters
Showing results (241-250 of 263) with videos related to
Page
of 27
Sort By:
Antimicrobial Agents and Chemotherapy
|
November 19, 2008
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations
V V Hynninen, K T Olkkola, L Bertilsson, et al.
EXS
|
January 1, 1994
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity
M Ingelman-Sundberg, I Johansson, I Persson, et al.
Lancet (London, England)
|
January 2, 1993
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
L Bertilsson, M L Dahl, F Sjöqvist, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1979
Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression
L Träskman, M Asberg, L Bertilsson, et al.
British Journal of Clinical Pharmacology
|
September 19, 2001
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
H K Roh, J Y Chung, D Y Oh, et al.
Pharmacogenetics
|
December 11, 1999
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
M L Bernal, B Sinues, I Johansson, et al.
Pharmacogenetics
|
April 1, 1993
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes
L Bertilsson, C O Meese, Q Y Yue, et al.
British Journal of Clinical Pharmacology
|
December 1, 1996
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
Y Böttiger, P Dostert, M S Benedetti, et al.
European Journal of Clinical Pharmacology
|
January 1, 1991
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
I Johansson, Q Y Yue, M L Dahl, et al.
The Pharmacogenomics Journal
|
October 24, 2012
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
A Habtewold, W Amogne, E Makonnen, et al.
Page
of 27
Search research articles
Search
Showing results (241-250 of 263) with videos related to
Sort By:
Page
of 27
Antimicrobial Agents and Chemotherapy
|
November 19, 2008
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations
V V Hynninen, K T Olkkola, L Bertilsson, et al.
EXS
|
January 1, 1994
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity
M Ingelman-Sundberg, I Johansson, I Persson, et al.
Lancet (London, England)
|
January 2, 1993
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
L Bertilsson, M L Dahl, F Sjöqvist, et al.
Clinical Pharmacology and Therapeutics
|
November 1, 1979
Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression
L Träskman, M Asberg, L Bertilsson, et al.
British Journal of Clinical Pharmacology
|
September 19, 2001
Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients
H K Roh, J Y Chung, D Y Oh, et al.
Pharmacogenetics
|
December 11, 1999
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
M L Bernal, B Sinues, I Johansson, et al.
Pharmacogenetics
|
April 1, 1993
Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes
L Bertilsson, C O Meese, Q Y Yue, et al.
British Journal of Clinical Pharmacology
|
December 1, 1996
Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
Y Böttiger, P Dostert, M S Benedetti, et al.
European Journal of Clinical Pharmacology
|
January 1, 1991
Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
I Johansson, Q Y Yue, M L Dahl, et al.
The Pharmacogenomics Journal
|
October 24, 2012
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
A Habtewold, W Amogne, E Makonnen, et al.
Page
of 27